Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 211

1.

Calprotectin could be a potential biomarker for acute appendicitis.

Ambe PC, Gödde D, Bönicke L, Papadakis M, Störkel S, Zirngibl H.

J Transl Med. 2016 Apr 27;14(1):107. doi: 10.1186/s12967-016-0863-3.

2.

Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.

von Rundstedt FC, Rajapakshe K, Ma J, Arnold JM, Gohlke J, Putluri V, Krishnapuram R, Piyarathna DB, Lotan Y, Gödde D, Roth S, Störkel S, Levitt JM, Michailidis G, Sreekumar A, Lerner SP, Coarfa C, Putluri N.

J Urol. 2016 Jun;195(6):1911-9. doi: 10.1016/j.juro.2016.01.039. Epub 2016 Jan 21.

3.

Aquaporin-1 and 8 expression in the gallbladder mucosa might not be associated with the development of gallbladder stones in humans.

Ambe PC, Gödde D, Zirngibl H, Störkel S.

Eur J Clin Invest. 2016 Mar;46(3):227-33. doi: 10.1111/eci.12586. Epub 2016 Jan 21.

PMID:
26707370
4.

Vimentin 3, the new hope, differentiating RCC versus oncocytoma.

von Brandenstein M, Puetz K, Schlosser M, Löser H, Kallinowski JP, Gödde D, Buettner R, Störkel S, Fries JW.

Dis Markers. 2015;2015:368534. doi: 10.1155/2015/368534. Epub 2015 Apr 7.

5.

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.

Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ.

Urol Oncol. 2015 May;33(5):204.e25-33. doi: 10.1016/j.urolonc.2015.02.013. Epub 2015 Mar 29.

PMID:
25823535
6.

Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039. Epub 2014 Nov 20.

PMID:
25445556
7.

Immunohistochemical analysis of cytochrome C oxidase facilitates differentiation between oncocytoma and chromophobe renal cell carcinoma.

Adam AC, Scriba A, Ortmann M, Huss S, Kahl P, Steiner S, Störkel S, Büttner R.

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):54-9. doi: 10.1097/PAI.0000000000000036.

PMID:
25265428
8.

Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of human non-small cell lung cancer.

Amendt C, Staub E, Friese-Hamim M, Störkel S, Stroh C.

Clin Cancer Res. 2014 Sep 1;20(17):4478-87. doi: 10.1158/1078-0432.CCR-13-3385. Epub 2014 Jun 19.

9.

Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice.

Bergmann L, Beck J, Bothe K, Brinkmann OA, Buse S, Goebell PJ, Grünwald V, Holzapfel K, Kübler H, Marschner NW, Mickisch G, Schultze-Seemann W, Siebels M, Siemer S, Störkel S, Gschwend JE.

Oncol Res Treat. 2014;37(3):136-41. doi: 10.1159/000360179. Epub 2014 Feb 21.

10.

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K.

Eur Urol. 2014 Aug;66(2):243-50. doi: 10.1016/j.eururo.2014.03.011. Epub 2014 Mar 21.

PMID:
24680359
11.

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.

Douillard JY, Pirker R, O'Byrne KJ, Kerr KM, Störkel S, von Heydebreck A, Grote HJ, Celik I, Shepherd FA.

J Thorac Oncol. 2014 May;9(5):717-24. doi: 10.1097/JTO.0000000000000141.

12.

[T1 bladder cancer: role of documentation for bladder tumor findings and targeted second resection].

Lazica DA, Böttcher S, Degener S, von Rundstedt FC, Brandt AS, Störkel S, Roth S.

Urologe A. 2013 Aug;52(8):1110-7. doi: 10.1007/s00120-013-3206-5. German.

PMID:
23754611
13.

[Impact of operator experience on TURB of high-grade non-muscle-invasive bladder cancer--analysis of 254 second resections at a university teaching hospital].

Lazica DA, Degener S, Böttcher S, Brandt AS, Störkel S, Roth S.

Aktuelle Urol. 2013 May;44(3):196-200. doi: 10.1055/s-0033-1345144. Epub 2013 May 27. German.

PMID:
23712276
14.

[T1 high-grade bladder cancer - value of second operation with prognostuic parameters of first operation: analysis of 167 cases].

Lazica DA, Böttcher S, Degener S, von Rundstedt FC, Brandt AS, Roth S, Störkel S, Mathers MJ.

Aktuelle Urol. 2013 Mar;44(2):124-8. doi: 10.1055/s-0033-1334962. Epub 2013 Apr 11. German.

PMID:
23580383
15.

Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis.

Bottke D, Golz R, Störkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T.

Eur Urol. 2013 Aug;64(2):193-8. doi: 10.1016/j.eururo.2013.03.029. Epub 2013 Mar 17.

PMID:
23522911
16.

Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test.

Rüschoff J, Kerr KM, Grote HJ, Middel P, von Heydebreck A, Alves VA, Baldus SE, Büttner R, Carvalho L, Fink L, Jochum W, Lo AW, López-Ríos F, Marx A, Molina TJ, Olszewski WT, Rieker RJ, Volante M, Thunnissen E, Wrba F, Celik I, Störkel S.

Arch Pathol Lab Med. 2013 Sep;137(9):1255-61. doi: 10.5858/arpa.2012-0605-OA. Epub 2012 Dec 27.

PMID:
23270410
17.

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F.

Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19.

PMID:
23265711
18.

Two papillary renal cell carcinomas of different origin following renal transplantation (Case report).

Gerth HU, Pohlen M, Thoennissen NH, Suwelack B, Pavenstädt HJ, Störkel S, Abbas M, Spieker T, Thölking G.

Oncol Lett. 2012 Jul;4(1):80-82. Epub 2012 May 4.

19.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ.

Lancet Oncol. 2012 Jan;13(1):33-42. doi: 10.1016/S1470-2045(11)70318-7. Epub 2011 Nov 4.

PMID:
22056021
20.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators.

Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk